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Previous studies have shown that “bioequivalent” generic products of vancomycin are less effective in vivo against Staphy-
lococcus aureus than the innovator compound. Considering that suboptimal bactericidal effect has been associated with
emergence of resistance, we aimed to assess in vivo the impact of exposure to innovator and generic products of vancomy-
cin on S. aureus susceptibility. A clinical methicillin-resistant S. aureus (MRSA) strain from a liver transplant patient with
persistent bacteremia was used for which MIC, minimum bactericidal concentration (MBC), and autolytic properties were
determined. Susceptibility was also assessed by determining a population analysis profile (PAP) with vancomycin concen-
trations from 0 to 5 mg/liter. ICR neutropenic mice were inoculated in each thigh with7.0 log10 CFU. Treatment with the
different vancomycin products (innovator and three generics; 1,200 mg/kg of body weight/day every 3 h) started 2 h later
while the control group received sterile saline. After 24 h, mice were euthanized, and the thigh homogenates were plated.
Recovered colonies were reinoculated to new groups of animals, and the exposure-recovery process was repeated until 12
cycles were completed. The evolution of resistance was assessed by PAP after cycles 5, 10, 11, and 12. The initial isolate dis-
played reduced autolysis and higher resistance frequencies than S. aureus ATCC 29213 but without vancomycin-
intermediate S. aureus (VISA) subpopulations. After 12 cycles, innovator vancomycin had significantly reduced resistant
subpopulations at 1, 2, and 3 mg/liter, while the generic products had enriched them progressively by orders of magnitude.
The great capacity of generic vancomycin to select for less susceptible organisms raises concerns about the role of thera-
peutic inequivalence of any antimicrobial on the epidemiology of resistance worldwide.
Generic intravenous antibiotics are accepted for clinical usesolely by fulfilling the requirement of pharmaceutical
equivalence (i.e., having similar concentrations of the active
ingredients), from which therapeutic equivalence (i.e., similar
efficacy and safety) is assumed. However, our research group
has shown that this assumption is not straightforward, and
many pharmaceutically equivalent generics fail in vivo, sug-
gesting that other factors, such as stability of the active phar-
maceutical ingredient (API), excipients, and apparently inno-
cent impurities may have a role in determining in vivo efficacy
(15, 21, 23).
In the case of vancomycin, we demonstrated that despite sim-
ilar or even higher concentrations of the API, indistinguishable in
vitro activity, and “bioequivalent” pharmacokinetics, generic
products killed significantly fewer bacteria (several orders ofmag-
nitude) in a murine thigh infection model and in some cases dis-
played the Eagle effect (paradoxical antagonistic effect at the high-
est dose) (21). Considering that “dead bugs don’t mutate” (19)
and that vancomycin resistance in S. aureus is a growing concern,
manifested by isolation of vancomycin-intermediate Staphylococ-
cus aureus ([VISA] MIC of 4 to 8 mg/liter) and vancomycin-
resistant S. aureus (VRSA) strains (MIC of 16 mg/liter), we
aimed to determine if the in vivo exposure to generic bioequiva-
lent products with inferior bactericidal efficacy favored the emer-
gence of resistance in S. aureus.
(Preliminary results of this work were presented at the 46th
Interscience Conference on Antimicrobial Agents and Chemo-
therapy, San Francisco, CA, 27 to 30 September 2006 [14]).
MATERIALS AND METHODS
Strain. A clinical methicillin-resistant S. aureus (MRSA) strain from the
blood of a liver transplant patient with persistent bacteremia was recov-
ered after 10 days of treatment with generic vancomycin and stored at
70°C under the identification code S. aureus GRP-0109 (for a full de-
scription anddiscussion of the case, see Rodriguez et al. [13]). The identity
of the isolate was confirmed by coagulase and mannitol fermentation
tests. Mueller-Hinton broth (MHB) andMueller-Hinton agar (MHA) or
Trypticase soy agar (TSA) (Difco, BectonDickinson) was used for routine
liquid and solid cultures, respectively. For population analysis profiles
(PAP) brain heart infusion agar (BHIA) was employed (Difco, Becton
Dickinson) (see below). All bacterial counts were expressed as log10 CFU.
Susceptibility testing. Vancomycin minimal inhibitory and bacteri-
cidal concentrations (MIC andMBC)were determined by brothmicrodi-
lution according to the CLSI, using S. aureusATCC29213 as a control (3).
For PAP, a log-phase culture of 8 to 9 log10 CFU/ml was plated on BHIA
plates containing 0, 1, 2, 3, 4, and 5mg/liter of vancomycin (Vancocin CP;
Eli Lilly [Lilly]) in triplicate and incubated aerobically at 37°C for 48 h
following the methodology described by Hiramatsu et al. (8). The area
under the vancomycin concentration versus the log10 CFU/ml curve
(AUC) was calculated with Prism, version 5.0 (GraphPad, San Diego,
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CA), and the resistance frequency at each concentration was determined
by dividing the number of CFU that grew in antibiotic-containing agar by
the total population in antibiotic-free plates. Population analysis profiles
were performed with S. aureus GRP-0109 after it was isolated from the
patient (baseline PAP) and after 5, 10, 11, and 12 cycles of treatment with
innovator or generic vancomycin (postexposure PAP) or sterile saline
(control).
Autolysis assay. Triton X-100-induced autolysis of S. aureus GRP-
0109 was measured with the assay described by Gustafson et al. (7): a
log-phase culture containing 8.0 log10 CFU/ml was centrifuged at 13,000
rpm for 10 min at 4°C, the supernatant was removed, and the pellet was
suspended in sterile chilled water. After another centrifugation under the
same conditions, the pellet was resuspended in 0.05 M Tris-HCl adjusted
to a pH of 7.4 until the culture reached an optical density at 580 nm
(OD580) of 1.00. TritonX-100was added to a final concentration of 0.05%
(vol/vol), and the tube was incubated statically at 37°C for 4 h. Every 30
min the absorbance was measured by spectrophotometry (Spectro 22;
Labomed, Culver City, CA) and registered as a percentage of the initial
OD. S. aureusATCC 29213 was used as the control strain. Three indepen-
dent assays were performed in duplicate.
Antibiotics. The innovator product of vancomycin from Eli Lilly
(Mexico) and generics fromAbbott (Chicago, IL), American Pharmaceu-
tical Partners ([APP] Los Angeles, CA), and Proclin (Laboratories Nor-
thia, Buenos Aires, Argentina) were purchased at reputable drugstores
and prepared according to the manufacturers’ instructions (in the text
products are referred to by themanufacturer’s name). The reference pow-
der from the U.S. Pharmacopeia ([USP] Rockville, MD) was used for
microdilution susceptibility testing. The lots of all the products are listed
in Table 1.
Animals. For in vivo experiments, 6-week-old murine-pathogen-free
Udea:ICR(CD-1) femalemice weighing 23 to 27 g were used. The animals
had water and food ad libitum, and all the procedures were approved by
the University of Antioquia animal experimentation ethics committee.
In vivo exposure. For the first passage 12 mice were rendered neutro-
penic with two intraperitoneal doses of cyclophosphamide: 150 mg/kg
and 100 mg/kg at 4 and 1 days before infection, respectively. This treat-
ment induces profound neutropenia (10 neutrophils/l) during 4 days
(24).
Fourteen hours after the last dose of cyclophosphamide (hour 2),
the animals were inoculated in both thighs with 0.1 ml of a log-phase
culture in MHB containing 8.0 log10 CFU/ml of S. aureus GRP-0109.
Two hours later (hour 0), vancomycin treatment was started at 1,200
mg/kg of body weight per day by subcutaneous injections every 3 h (q3h)
in groups of two mice per product (innovator and three generics) plus a
control group that received sterile saline. The researchers were blind to
these treatment groups from the inception of the project, and the codewas
opened only after the analysis of data was finished. In this model such a
dose corresponds to a free area under the concentration-time curve
(fAUC)/MIC of 1,068 h, which is eight times and four times the magni-
tude required for maximal efficacy of vancomycin based on our findings
(21) and those of others (16), respectively. The reason to choose this dose
was that the Eagle effect wasmost pronounced at 1,200mg/kg per day, and
we hypothesized that it would provide the highest probability of selecting
less susceptible subpopulations. After 24 h, mice were sacrificed by cervi-
cal dislocation; the thighs were resected, homogenized in sterile saline to a
final volume of 10 ml, serially diluted, and plated on MHA for CFU de-
termination. Simultaneously, 1 ml of the homogenate was centrifuged
twice at 10,000 g for 10 min to eliminate residual antibiotic (carryover)
and resuspended in sterile saline; from this a 100-l sample was plated by
confluence on MHA (one plate per thigh, four plates per treatment
group). These plates were incubated at 37°C for 24 h and then stored at
4°C until the next passage.
From the second passage on, the inoculum for each treatment group
(four vancomycin products and the saline control) was prepared by re-
suspending all the colonies recovered from the four dishes of the previous
passage (to ensure high bacterial population representation) in 10 ml of
MHB, and, after a 1:100 dilution in fresh MHB, the inoculum was incu-
bated at 37°C until an OD580 corresponding to 8 log10 CFU/ml was
reached. Six neutropenic mice per group were inoculated with 0.1 ml in
both thighs: two were sacrificed at 0 h (pretreatment group), two received
vancomycin at 1,200 mg/kg per day divided q3h and were sacrificed 24 h
later (posttreatment group), and two were injected with saline (infected,
nontreated intragroup controls). A separate group of two animals per
passage received saline injections (infected but untreated controls). After
24 h, the animals were processed as described above to determine bacterial
growth and antimicrobial effect and to prepare the inoculum for the next
passage. The cycle was repeated until 12 passages were completed;
follow-up of mutant selection after the fifth passage allowed the research-
ers to stop vancomycin exposure at this point to prevent unnecessary
suffering of experimental animals without compromising the statistical
power of the study.
Data analysis. (i) Autolysis assay.Absorbance data from theTriton-X
assay were expressed as percentages of the original OD values and ana-
lyzed by linear regression with Prism, version 5.0, to compare the slopes
and intercepts of S. aureusGRP-0109 and ATCC 29213 by the overall test
for coincidence of linear regressions (curve fitting analysis).
(ii) Population analysis profile and resistance frequency. The area
under the vancomycin concentration versus the log10 CFU/ml curve was ob-
tainedwith Prism, version 5.0, for each treatment group. The intensity of the
effect (IE) (6)was calculatedas thedifferencebetween theAUCsof the control
and treated groups by the following formula: IEAUCcontrolAUCtreated.
As each group yielded three IE values, means were compared by anal-
ysis of variance (ANOVA), followed by Dunnett’s posthoc test. Addition-
ally, the resistance frequency (RF) at 1, 2, and 3 mg/liter of vancomycin
was determined by dividing the number of CFU growing in antibiotic-
containing agar by the total number of bacteria in the population (grown
in antibiotic-free agar) and expressed in negative logarithms. CFU counts
at 4 and 5mg/liter were below the limit of detection, so no exact RF could
be calculated. Changes inRF (final RF initial RF)were obtained for each
group and concentration and compared by Student’s t test.
RESULTS
Initial susceptibility profile. S. aureus GRP-0109 was identified
by automatic testing (Vitek 2; bioMérieux,Marcy l’Etoile, France)
as resistant to penicillin G, oxacillin, macrolides, lincosamides,
and aminoglycosides and susceptible to vancomycin, rifampin,
tetracyclines, and sulfonamides. Table 2 shows the confirmation
TABLE 1 Vancomycin products
Product name (manufacturer) Batch/lot no.
Vancocin CP (Eli Lilly, Mexico) A050370, A048213
Vancomycin USP (APP, USA) 121384
Vancomicina USP (Abbott, USA) 09993Z7, 09993Z8, 18879Z7,
19236TB21
Vancomicina Proclin (Laboratories
Northia, Argentina)
8441, 8690, 8872
TABLE 2 Antibiotic MICs and MBCs for S. aureus GRP-0109 by broth
microdilution
Antibiotic
MIC
(mg/liter)
MBC
(mg/liter)
Susceptibility
of isolate
Penicillin G 32 32 Resistant
Oxacillin 8 8 Resistant
Gentamicin 32 32 Resistant
Vancomycin 1 2 Susceptible
Rodriguez et al.
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results from broth microdilution susceptibility testing to penicil-
lin G, oxacillin, gentamicin, and vancomycin.
Figure 1 displays the initial PAP with the respective resistance
frequencies for vancomycin from 1 to 5mg/liter. As frequencies at
concentrations of4 mg/liter were6.0 logs, a heterogeneous
VISA (hVISA) phenotype was ruled out, but comparison with the
PAP of reference strain S. aureus ATCC 29213 showed an altered
susceptibility pattern with increased resistant subpopulations.
Autolytic profile. Control strain ATCC 29213 exhibited a
45.3% decrease in absorbance after exposure to Triton X-100,
while GRP-0109 displayed a reduction of 21.2%, indicating resis-
tance to autolysis in this strain relative to its control. The differ-
ence in autolysis profiles is shown in Fig. 2 as two independent
linear regressions with significantly different slopes (P 0.0001),
indirectly confirming cell wall alterations of S. aureus GRP-0109.
Postexposure susceptibility changes. Selection of less suscep-
tible cells at 2 mg/liter was evident after 5 cycles for one vancomy-
cin product (corresponding to Proclin after the blinding code was
opened) and 10 cycles for two products (APP and Abbott). Resis-
tance to vancomycin at 3 mg/liter required 11 cycles to appear
(Proclin). After cycle 12, the same three vancomycin products
were consistently selecting cells resistant to 2 and 3 mg/liter. One
product (corresponding to Lilly) was characterized for the oppo-
site tendency; i.e., it suppressed resistant subpopulations.
Figure 3 shows the PAP after 12 passages in vivo. Innovator
vancomycin (Lilly) reduced resistant subpopulations (indicated
by a smaller AUC and a left shift of the PAP curve compared with
the baseline) while generics enriched them, as shown by greater
AUCs or right shift of the PAP curves along the x axis. The global
impact of the exposure can be seen in the intensity of effects in Fig.
4 comparing treatment groups with the control. Lilly was the only
product that reduced the AUC (IE 0.22) while generics signifi-
cantly enlarged it (IE values of1.83,2.68, and6.07 for APP,
Abbott, and Proclin, respectively; P 0.0001 by ANOVA). Figure
5 shows the change in resistance frequencies (final RF initial RF)
after in vivo exposure at concentrations from 1 to 3 mg/liter: Lilly
reduced resistant cells at all concentrations by approximately 1
order of magnitude while generics enriched them at 2 mg/liter
(from10 to 1,000-fold), andProclin also increased cells growing at
3 mg/liter by 10-fold. In the mock-treated control group (sterile
saline injections), all subpopulations diminished by approxi-
mately 1 log10, reaching resistance frequencies similar to those of
the susceptible strain ATCC 29213 (Fig. 1).
FIG 1 Vancomycin population analysis profile of S. aureus GRP-0109 after
being isolated from a patient with persistent bacteremia and unsuccessful ge-
neric treatment, indicating altered susceptibility in comparison with strain
ATCC 29213: 10 times more cells were able to grow at 1 mg/liter of vancomy-
cin, 4 times more grew at 2 mg/liter, and 2.5 times more grew at 3 mg/liter
(resistance frequency data at right).
FIG 2 Triton X-100 autolysis assay. Compared with S. aureus ATCC 29213,
the strain GRP-0109 exhibited a reduced autolysis profile (45% versus 21%),
one of the first steps toward vancomycin resistance.
FIG 3 Pre- and postexposure PAP of S. aureus GRP-0109 (AUC in parenthe-
ses). Values for the initial isolate are plotted. Treatment with innovator van-
comycin (Lilly) caused a down and left curve shift, indicating a reduction of the
less susceptible subpopulations, which is sharply different from three generics,
which had higher AUCs and up and/or right displacement of the curve, (espe-
cially Proclin), due to resistant subpopulation enrichment. The control saline
group exhibited a down and left displacement, consistent with reversion of
unstable resistance associated with reduced fitness. The limit of detection for
all of the postexposure isolates was 10 CFU/ml, and for the GRP-0109 initial
strain the limit was 0 CFU/ml.
Generic Vancomycin and Resistance
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Reversion of resistance phenotype. After the 12 passages were
completed, the strainswere kept in agar plates at 4°Cwithmonthly
subcultures. After 2 months, PAP were performed again, and the
results were similar to those with the control sterile saline group,
indicating reversion of resistance and recovery of the preexposure
pattern of susceptibility (data not shown). Unfortunately, this was
an unexpected outcome, and no additional tests could be per-
formed on the isolates.
DISCUSSION
Wedemonstrated previously that generic products of vancomycin
had inferior efficacy in vivo despite pharmaceutical equivalence,
bioequivalence, and indistinguishable MIC and MBC values (13,
21). The same problem was demonstrated with oxacillin (15) and
gentamicin (23), confirming that current criteria for approval of
generic antibiotics do not ensure therapeutic equivalence and that
the impact of other factors, such as antagonistic impurities, the
quality of excipients, or in vivo instability of the API may cause
therapeutic failures in generic antibacterials that are otherwise
“equivalent” to their respective innovators. The data shown in this
paper reveal that resistance, the natural consequence of subopti-
mal treatment of infections, is efficiently promoted by inequiva-
lent generics of vancomycin.
Suboptimal efficacy of vancomycin generics led to the hypoth-
esis that exposure to these products could select for less suscepti-
ble subpopulations of S. aureus. We chose an MRSA strain (S.
aureus GRP-0109) from a patient treated unsuccessfully for 10
days with generic vancomycin (13). The patient did not have risk
factors associated with persistent bacteremia: endocarditis, re-
tained devices, metastatic foci of infection, septic shock, diabetes
mellitus, or a strain with a vancomycin MIC of 2 mg/liter (10,
12, 22); and, notably, 48 h after the patient was switched to the
innovator drug, blood cultures became sterile, strongly suggesting
that the therapeutic failure was due to the generic vancomycin. As
shown by the Triton X-100 assay, S. aureus GRP-0109 had an
altered autolysis profile (Fig. 2), one of the first steps toward van-
comycin resistance (2), and exhibited a right-shifted PAP curve
comparedwith that of S. aureusATCC29213 (Fig. 1). Considering
that GRP-0109 was not the initial isolate of the patient but was
recovered after 10 days of therapy, we do not know with certainty
if these resistance features predated treatment or were induced by
it; however, the fact that they were exacerbated under further ge-
neric exposure inmice with the same product (Abbott) and others
(APP and Proclin), while they reverted under innovator pressure
and saline “treatment,” favors the hypothesis that generic vanco-
mycin induced them in both the patient (10-day exposure) and
the animal model (12-day exposure).
The spontaneous resistance frequency of our strain to vanco-
mycin (i.e., at 4 mg/liter) was 7.18 logs (1 resistant mutant for
every 15.8million cells) (Fig. 1). Considering that the inoculum in
the in vivo model was 7.0 log10 CFU/g (below the resistance fre-
quency), it is not surprising that we could not find hVISA or VISA
levels of resistance (as currently defined by regulatory agencies)
after exposure, but we did find significant enrichment of sub-
populations growing at vancomycin concentrations of 1 (MIC), 2
(susceptibility breakpoint), and 3 (nonsusceptible) mg/liter, all
with resistance frequencies greater than7.0 logs. As mentioned
above, these alterations reverted once the antibiotic pressure was
withdrawn, suggesting an adaptive or unstable nature.
Sieradzki and Tomasz (18) reported that exposure of a suscep-
tible S. aureus strain to subinhibitory concentrations of vancomy-
cin induces a transitory VISA-like phenotype characterized by re-
duced autolysis and increased cell wall thickness. They found that
vancomycin molecules trapped in the outer layers of the cell wall
(i.e., bound to free, unprocessed D-Ala-D-Ala termini) inhibit the
action of murein hydrolases and lysostaphin, blocking access to
their substrates by steric hindrance. If generics contain more im-
purities and degradation products than the innovator (like
FIG 5 Changes in resistance frequencies (RFs) to 1, 2, and 3 mg/liter of van-
comycin after in vivo exposure to innovator vancomycin (Lilly), generic ver-
sions (APP, Abbott, and Proclin), or sterile saline. At 1 mg/liter, compared to
initial values (GRP-0109), Lilly reduced the RFs by almost 10-fold, while ge-
nerics induced no significant change. At 2 mg/liter Lilly also reduced the RFs,
but generic products significantly increased them 10- to 1,000-fold. At 3 mg/
liter, again Lilly reduced the RFs, APP and Abbott did not change the baseline
RF, and Proclin significantly increased it by 1 order ofmagnitude. In the saline
group RFs were reduced about 1 log10 at all concentrations. The asterisk indi-
cates that the postexposure value is significantly different from the preexpo-
sure value (Student’s t test): P values of 0.0002 and 0.0005 for Lilly and saline at
1 mg/liter, respectively; P values of 0.0258, 0.0012, 0.0002, 0.0001, and
0.0029 for Lilly, APP, Abbott, Proclin, and saline at 2 mg/liter, respectively; P
values of 0.0140, 0.0152, and 0.0094 for Lilly, Proclin, and saline at 3 mg/liter,
respectively. CFU counts at 4 mg/liter and higher were below the limit of
detection.
FIG 4 Overall changes in the AUC (intensity of the effect IE) after exposure to
innovator (Lilly) and generic (APP, Abbott, and Proclin) vancomycin prod-
ucts compared with the control group. Positive values indicate smaller AUCs,
i.e., a reduction of less susceptible subpopulations with Lilly, while negative
values indicate greater AUCs, i.e., enrichment of resistant subpopulations,
with APP, Abbott, and Proclin (ANOVA, P  0.0001; all comparisons of a
generic versus the innovator compound had a P value of0.05 by Dunnett’s
posthoc test).
Rodriguez et al.
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CDP-1, that also binds D-Ala-D-Ala), more molecules may be
trapped in the cell wall, blocking lysis and clogging the peptidogly-
can layers, as described by Cui et al. (4), which reduces the diffu-
sion of factor B to the lethal target in the outer membrane. This
could explain the lower bactericidal efficacy and favor the enrich-
ment of subpopulations with higher MICs carrying mutations in
regulatory genes of the cell wall synthesis and stress response (9).
Last year (21), we reported that generics were ineffective at 1,200
mg/kg per day; it is remarkable that Proclin, the generic with the
greatest impact on resistance in this paper, was precisely the one
that displayed the greatest Eagle effect at this dose. It suggests that
the further a generic is from the innovator in terms of in vivo
efficacy, the greater is its power to select for resistant subpopula-
tions.
Asmentioned earlier, the strains reverted to amore susceptible
phenotype after passages without vancomycin, precluding addi-
tional experiments to define their resistance mechanisms. The re-
version of VISA strains was first reported by Boyle-Vavra et al.
after 15 daily passages in antibiotic-free medium, probably due to
the high metabolic burden and reduced fitness associated with
vancomycin resistance, which is maintained only under continu-
ous selective pressure (1). Future projects in the same line would
include electron microscopy to measure the thickness of the cell
wall (5) after innovator and generic product exposure, cell wall
composition analysis, evaluation of the cell wall stimulon re-
sponse (20) to different versions of vancomycin, and whole-
genome sequencing to identify potential mutations contributing
to resistance (11).
Our results suggest that the use of inequivalent generic prod-
ucts of vancomycin can contribute to resistance and therapeutic
failures as even minor MIC increments have a huge impact on
clinical outcome (17). Intermediate vancomycin resistance in S.
aureus is a slow, progressive process; thus longer treatment
courses with generic vancomycin (as seen in humans) can proba-
bly lead to the isolation of hVISA and VISA strains. Considering
the enormous amount of generic antibiotics prescribed in the
world, the fact that no proof of in vivo efficacy is currently required
for their approval, and our previous results of therapeutic in-
equivalence, these preliminary data of resistance enrichment by
generic antibiotics reinforce the suggestion that more stringent
criteria for generic approvals should be required.We are currently
working to expand this hypothesis to different antibiotic-
bacterium combinations, especially those with rapid development
and well-defined mechanisms.
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